Lipid Metabolism as a Potential Target of Liver Cancer
Kangze Wu,Feizhuan Lin
DOI: https://doi.org/10.2147/jhc.s450423
2024-02-14
Journal of Hepatocellular Carcinoma
Abstract:Kangze Wu, Feizhuan Lin Department of Hepatobiliary Surgery, Shaoxing People's Hospital, Shaoxing, People's Republic of China Correspondence: Feizhuan Lin, Department of Hepatobiliary Surgery, Shaoxing People's Hospital, Shaoxing, People's Republic of China, Email Hepatocellular carcinoma (HCC) stands as a severe malignant tumor with a profound impact on overall health, often accompanied by an unfavorable prognosis. Despite some advancements in the diagnosis and treatment of this disease, improving the prognosis of HCC remains a formidable challenge. It is noteworthy that lipid metabolism plays a pivotal role in the onset, development, and progression of tumor cells. Existing research indicates the potential application of targeting lipid metabolism in the treatment of HCC. This review aims to thoroughly explore the alterations in lipid metabolism in HCC, offering a detailed account of the potential advantages associated with innovative therapeutic strategies targeting lipid metabolism. Targeting lipid metabolism holds promise for potentially enhancing the prognosis of HCC. Keywords: cholesterol, fatty acid, hepatocellular carcinoma, lipid uptake, lipid catabolism, lipid synthesis Liver cancer significantly impacts human health, ranking as the sixth most common malignant tumor and the third leading cause of cancer-related deaths globally. Hepatocellular carcinoma (HCC) constitutes roughly 75%-85% of liver cancer cases. Multiple factors contribute to the development of HCC, including aflatoxin exposure, alcohol consumption, hepatitis B, hepatitis C, obesity, and other related elements. In high-risk regions like China, Korea, and sub-Saharan Africa, chronic HBV infection and aflatoxin exposure are predominant causes. 1 Over time, primary risk factors for HCC have shifted. In several regions, the proportion of HCC cases linked to obesity and diabetes has progressively risen. 2 Western countries are witnessing an increase in HCC incidence due to non-alcoholic fatty liver disease, particularly non-alcoholic steatohepatitis (NASH), associated with metabolic syndrome or diabetes. 3 While advancements have been made in comprehending the pathophysiology of HCC, it remains a formidable disease. 3 Typically diagnosed at advanced stages, HCC often presents a poor prognosis. In the United States, HCC patients have alarming survival rates. The average one-year survival rate is less than 50%, and the average five-year survival rate is less than 10%. 4 This underlines the urgency to enhance early detection and more effective treatments to improve the outlook for individuals diagnosed with HCC. Numerous conventional treatments are available for HCC, selected according to the patient's health status. Early-stage HCC patients are typically recommended for resection, transplantation, or local ablation. Intermediate-stage patients often opt for transarterial chemoembolization (TACE), while those in the advanced stage generally receive systemic treatment as the primary approach. 5–7 Currently, surgical intervention remains the primary treatment for HCC. 5,8 However, a notable challenge post-surgery is the high recurrence rate, which can be as high as 70% even in patients with a single tumor of 2cm or less. 9 In the last decade, sorafenib has stood out as a classic systemic drug with therapeutic effectiveness against HCC. 10 Advanced understanding of HCC development mechanisms has led to the establishment of anti-PD-L1 antibody atezolizumab and anti-vascular endothelial growth factor antibody bevacizumab as standard treatments for untreated advanced HCC, demonstrating superior effectiveness to sorafenib. 11,12 Yet, current treatments have limitations, stimulating researchers to actively search for new therapeutic targets. Among these, lipid metabolism has emerged as a notably promising focus of interest. 13–17 The liver, a vital organ, performs various physiological functions, including the intricate processing of lipids. 18 Lipids, comprising fats and lipoids, are diverse nutrients widely distributed in cellular organelles and serve as fundamental components of cellular membranes. 19 Central to the synthesis, storage, and breakdown of lipids, the liver plays a critical role in maintaining lipid balance within the body. One notable trait of cancer metabolism involves the promotion of de novo lipid synthesis, a pivotal pathway responsible for the generation of fatty acids (FAs). 20 This metabolic shift is essential for rapidly dividing tumor cells to acquire necessary lipids, crucial for membrane construction, energy supply, and post-translational modifications. 21 Relevant studies on lipid metabolism in HCC have already been published. Studies indicate that non-coding RNA c -Abstract Truncated-
oncology